| Name | Title | Contact Details |
|---|
Shield Healthcare offers a dynamic work environment with competitive salaries and a comprehensive benefits package. Check out our careers section for exciting opportunities.
Novoste div Best Vascular, is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biomed Resource is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Argen Corporation is the world`s largest manufacturer of precious dental gold alloys, leader in zirconia manufacturing, and leading innovator of digital dentistry solutions and scrap refining services. With more than 50 years serving the dental industry, Argen now distributes to more than 100 countries with subsidiaries in Canada, China, Germany and the United Kingdom. Argen enables dental labs of all sizes to integrate digital into every aspect of their workflow by offering a wide range of digitally-produced products and services. Argen is proud to be a family-owned American company that manufactures the highest quality products in the US and is dedicated to treating customers like family.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.